Suzhou Ribo Life Science (6938) Announces Phase II Clinical Trial Approval for RBD5044

Bulletin Express01-23 07:03

On January 23, 2026, Suzhou Ribo Life Science (6938) announced that its self-developed RBD5044 Injection received approval for a Phase II clinical trial from the National Medical Products Administration in China.

RBD5044 is an siRNA therapy targeting APOC3, a liver-synthesized protein that plays a critical role in lipid metabolism and is connected with hypertriglyceridemia complications. The approval allows further evaluation of RBD5044 in managing lipid disorders. The announcement notes that RBD5044 Injection may not ultimately be successfully developed or commercialized, prompting shareholders and potential investors to exercise caution.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1142966352?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-23 07:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142966352","market":"us","top_or_hot":-1,"title":"Suzhou Ribo Life Science (6938) Announces Phase II Clinical Trial Approval for RBD5044","media":"Bulletin Express","content":"<p>On January 23, 2026, Suzhou Ribo Life Science (6938) announced that its self-developed RBD5044 Injection received approval for a Phase II clinical trial from the National Medical Products Administration in China.</p>\n<p>RBD5044 is an siRNA therapy targeting APOC3, a liver-synthesized protein that plays a critical role in lipid metabolism and is connected with hypertriglyceridemia complications. The approval allows further evaluation of RBD5044 in managing lipid disorders. The announcement notes that RBD5044 Injection may not ultimately be successfully developed or commercialized, prompting shareholders and potential investors to exercise caution.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Suzhou Ribo Life Science (6938) Announces Phase II Clinical Trial Approval for RBD5044</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSuzhou Ribo Life Science (6938) Announces Phase II Clinical Trial Approval for RBD5044\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-01-23 07:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On January 23, 2026, Suzhou Ribo Life Science (6938) announced that its self-developed RBD5044 Injection received approval for a Phase II clinical trial from the National Medical Products Administration in China.</p>\n<p>RBD5044 is an siRNA therapy targeting APOC3, a liver-synthesized protein that plays a critical role in lipid metabolism and is connected with hypertriglyceridemia complications. The approval allows further evaluation of RBD5044 in managing lipid disorders. The announcement notes that RBD5044 Injection may not ultimately be successfully developed or commercialized, prompting shareholders and potential investors to exercise caution.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06938","symbol_name":"瑞博生物-B","start_time":0,"source_url":"","article_id":"1142966352","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142966352","pubTimestamp":1769122985,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On January 23, 2026, Suzhou Ribo Life Science (6938) announced that its self-developed RBD5044 Injection received approval for a Phase II clinical trial from the National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06938":"瑞博生物-B"},"translate_title":"苏州日博生命科学（6938）公布RBD5044的II期临床试验批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1},"content_text":"On January 23, 2026, Suzhou Ribo Life Science (6938) announced that its self-developed RBD5044 Injection received approval for a Phase II clinical trial from the National Medical Products Administration in China.\nRBD5044 is an siRNA therapy targeting APOC3, a liver-synthesized protein that plays a critical role in lipid metabolism and is connected with hypertriglyceridemia complications. The approval allows further evaluation of RBD5044 in managing lipid disorders. The announcement notes that RBD5044 Injection may not ultimately be successfully developed or commercialized, prompting shareholders and potential investors to exercise caution.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142966352","isCrawlerRequest":true}